Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
$20.78
-2.7%
$24.50
$2.45
$38.33
$1.31B1.46351,908 shs207,156 shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$92.20
-1.4%
$100.35
$13.97
$155.29
$1.37B3.31320,622 shs263,338 shs
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$4.37
+4.0%
$5.52
$3.60
$10.99
$329.79M1.38662,642 shs624,798 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$31.53
+0.9%
$43.88
$23.57
$60.08
$1.27B0.46363,698 shs182,975 shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
-2.72%-1.09%-13.99%-27.09%+512.98%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-1.43%+5.96%-21.83%+34.13%+528.07%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
+4.05%0.00%-24.13%-34.38%-3.10%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+0.86%-2.78%-10.58%-36.26%+29.27%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
$20.78
-2.7%
$24.50
$2.45
$38.33
$1.31B1.46351,908 shs207,156 shs
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$92.20
-1.4%
$100.35
$13.97
$155.29
$1.37B3.31320,622 shs263,338 shs
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$4.37
+4.0%
$5.52
$3.60
$10.99
$329.79M1.38662,642 shs624,798 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$31.53
+0.9%
$43.88
$23.57
$60.08
$1.27B0.46363,698 shs182,975 shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
-2.72%-1.09%-13.99%-27.09%+512.98%
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-1.43%+5.96%-21.83%+34.13%+528.07%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
+4.05%0.00%-24.13%-34.38%-3.10%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+0.86%-2.78%-10.58%-36.26%+29.27%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
2.91
Moderate Buy$42.43104.18% Upside
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.33
Hold$150.0062.69% Upside
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
2.88
Moderate Buy$20.14360.93% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.14
Hold$38.8023.06% Upside

Current Analyst Ratings Breakdown

Latest LXEO, PAHC, INBX, and DMRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/12/2026
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
Reiterated RatingOutperform$35.00
6/11/2026
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
Initiated CoverageBuy$45.00
6/8/2026
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
Initiated CoverageBuy
5/29/2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
DowngradeSell (D-)Sell (E+)
5/28/2026
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
Initiated CoverageOutperform$35.00
5/21/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeStrong-BuyHold
5/15/2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
UpgradeSell (E+)Sell (D-)
5/14/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Lower Price TargetNeutral$62.00 ➝ $44.00
5/11/2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Reiterated RatingBuy$17.00
5/8/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeBuy (B)Buy (B-)
5/1/2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
DowngradeSell (D-)Sell (E+)
(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/AN/AN/AN/A($110.11) per shareN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.30M1,040.44N/AN/A$0.55 per share167.64
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
N/AN/AN/AN/A$3.38 per shareN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B0.99$3.30 per share9.56$7.05 per share4.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
-$209.84M-$5.58N/AN/AN/AN/A-428.30%-114.62%8/5/2026 (Estimated)
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$140.05M-$8.39N/AN/AN/AN/A-563.90%-72.32%8/12/2026 (Estimated)
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$99.96M-$1.45N/AN/AN/AN/A-47.48%-41.72%8/13/2026 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$2.3313.539.470.476.35%37.14%8.57%6/30/2026 (Confirmed)

Latest LXEO, PAHC, INBX, and DMRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$1.6750-$2.15-$0.4750-$2.15N/AN/A
5/13/2026Q1 2026
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
-$0.3878-$0.62-$0.2322-$0.62N/AN/A
5/11/2026Q1 2026
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$0.29-$0.25+$0.04-$0.25N/AN/A
5/6/2026Q3 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72$0.76+$0.04$0.59$367.02 million$383.54 million
3/30/2026Q4 2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$0.32-$0.27+$0.05-$0.27N/AN/A
3/19/2026Q4 2025
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.08-$2.11-$0.03-$2.11N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/AN/AN/AN/AN/A
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.52%N/A20.60%N/A

Latest LXEO, PAHC, INBX, and DMRA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.51%6/3/20266/3/20266/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
N/A
22.49
22.48
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
12.58
6.46
6.46
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
N/A
14.16
14.16
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.97
3.17
1.26
CompanyEmployeesShares OutstandingFree FloatOptionable
Damora Therapeutics, Inc. Common Stock stock logo
DMRA
Damora Therapeutics, Inc. Common Stock
4061.55 million61.31 millionNo Data
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.67 million11.99 millionOptionable
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
5878.52 million74.36 millionNot Optionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.56 million20.23 millionOptionable

Recent News About These Companies

Is PAHC Undervalued at 10x Earnings vs Peers?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Damora Therapeutics, Inc. Common Stock stock logo

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$20.78 -0.58 (-2.72%)
As of 06/12/2026 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$92.20 -1.34 (-1.43%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$92.43 +0.23 (+0.25%)
As of 06/12/2026 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Lexeo Therapeutics stock logo

Lexeo Therapeutics NASDAQ:LXEO

$4.37 +0.17 (+4.05%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$4.43 +0.06 (+1.49%)
As of 06/12/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$31.53 +0.27 (+0.86%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$31.57 +0.04 (+0.13%)
As of 06/12/2026 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.